We Help Companies Find New Sales Opportunities
Smith & Nephew
Smith & Nephew is to set up a 58,000 sq ft headquarters at Croxley Green Business Park near Watford.
Smith & Nephew is planning to expand its wound management facility on Hessle Road in Hull, with the relocation of 53 jobs from York.
Smith & Nephew is to sell its plastic nets and foams factory in Gilberdyke to US-based DelStar Technologies, with the transfer of some of the 91 staff.
Smith & Nephew is to acquire the assets of Nucryst Pharmaceuticals, the US manufacturer of antimicrobial dressings, for £13m.
Smith & Nephew has acquired BlueSky Medical Group, the US developer of wound treatments, for up to £55m.
Smith & Nephew has acquired Plus Orthopedics, the Swiss manufacturer of replacement hips and knees, for £460m.
Smith & Nephew is in merger discussions with Biomet of the US, which could lead to the creation of a combined orthopaedic products group worth up to £10bn.
Smith & Nephew has acquired OsteoBiologics, the US supplier of bone graft substitutes, for £39m.
Smith & Nephew and Beiersdorf of Germany have sold their BSN medical products joint venture to Montagu Private Equity for £698m.
Smith & Nephew is to acquire Midland Medical Technologies, the Birmingham-based supplier of hip replacement products, for up to £100m.
Smith & Nephew has agreed to acquire Centerpulse, the Swiss medical technology company, for £1.5bn, creating the world's third largest orthopaedics group.
Smith & Nephew has sold its Rehabilitation business to AbilityOne of the US for £87m, creating a leading supplier of rehabilitation products to hospitals with operations in Kirkby, France and the US.
Smith & Nephew is to acquire Oratec Interventions, the US developer of radio frequency technology for minimally invasive surgery, for £220m.
Smith & Nephew, the medical devices group, is seeking acquisitions to expand its salesforce, and is interested in the Zimmer business being demerged from Bristol Myers Squibb.
Smith & Nephew is buying an advanced woundcare business from Beiersdorf for £30m, and is also forming a joint venture with the German company for the supply of bandages and castings.
Smith & Nephew is looking to spend up to £500m on acquisitions over the next few years, in order to expand its medical devices manufacturing business.
Smith & Nephew is to sell its consumer products division to a management team and Beiersdorf of Germany, in order to raise £235m and focus on its more profitable high-tech activities.
Smith & Nephew is buying Iruxol, the woundcare product, from BASF for £74m, and will seek approval to market the treatment in the UK, France, Australia and Japan.
Smith & Nephew is to acquire Exogen, the US manufacturer of ultrasound devices, for £40m.
Smith & Nephew is to sell a majority stake in its medical bracing business to Chase Capital Partners for £124m, and the proceeds will be used to expand its core orthopaedic, wound management, and endoscopy businesses.
Smith & Nephew, the healthcare concern, has acquired Yunhab Meditech and ChangMyung, its two South Korean distributors, for £4m.